The application of pseudotyped virus technology in the evaluation of prevention and control products for new emergent viral infectious disease

ABSTRACT

The experimental operation of new emergent infectious disease pathogens often needs to be carried out in a high-level biosafety laboratory. The laboratory operation of live virus and the transfer between labs bring a high level of safety risk, which results in difficulties with in vitro potency evaluation of vaccine and antibody drugs screening using live virus. With the improvement of biotechnology, pseudotyped virus technology can simulate the membrane structure of virus or the state of virus nucleic acid. The former can simulate the process of receptor binding, entering cell and antibody recognition of viral infection, and can replace the living virus for in vitro cell experiment and animal experiment in vivo. The latter can replace the living virus for quality control of nucleic acid detection. This paper reviews the application of pseudotyped virus technology in the evaluation of biotechnology products such as vaccines, antibodies, diagnostic reagents, etc., in order to provide reference for the application of pseudotyped virus technology in the basic research and product evaluation of SARS-CoV-2 prevention and control.